Peptide Comparison
PemvidutidevsSurvodutide
Balanced dual GLP-1/glucagon receptor agonist with no dose titration required and breakthrough therapy designation for MASH.
Dual GLP-1/glucagon receptor agonist for obesity and metabolic liver disease
At a Glance
Quick
comparison
Dose Range
Pemvidutide
1.2 mg–2.4 mg mg
Survodutide
2.4 mg–6 mg mg
Frequency
Pemvidutide
Once daily
Survodutide
Once daily
Administration
Pemvidutide
Subcutaneous injection
Survodutide
subcutaneous injection
Cycle Length
Pemvidutide
Ongoing/indefinite
Survodutide
Ongoing/indefinite
Onset Speed
Pemvidutide
Moderate (1-2 weeks)
Survodutide
Moderate (1-2 weeks)
Evidence Level
Pemvidutide
Moderate human trials (Phase 1-2)
Survodutide
Strong human trials (Phase 3 or FDA approved)
Efficacy
Benefit
ratings
Weight Loss
Liver Health
Metabolic Health
Weight Management
Blood Sugar Control
Technical Data
Compound
specifications
Pemvidutide
Molecular Formula
C182H275N39O54
Molecular Weight
3873.35 Da
Half-Life
Approximately 110 hours (4.6 days)
Bioavailability
Subcutaneous bioavailability consistent with glycolipid-conjugated peptide therapeutics
CAS Number
2538014-94-5
Survodutide
Molecular Formula
C192H289N47O61
Molecular Weight
4,231.6 Da
Half-Life
~7 days (enabling once-weekly dosing)
Bioavailability
Optimized for subcutaneous administration with C18 acylation
CAS Number
2805997-46-8
Applications
Best
suited for
Pemvidutide
Adults seeking substantial weight loss without complex dose titration
Pemvidutide is particularly well-suited for individuals focused on adults seeking substantial weight loss without complex dose titration. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach.
Individuals with concurrent MASH/NAFLD and obesity requiring dual-target therapy
Pemvidutide is particularly well-suited for individuals focused on individuals with concurrent mash/nafld and obesity requiring dual-target therapy. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach.
Patients with metabolic syndrome who need comprehensive risk factor improvement
Pemvidutide is particularly well-suited for individuals focused on patients with metabolic syndrome who need comprehensive risk factor improvement. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach.
Those interested in investigational dual agonist therapies with strong early data
Pemvidutide is particularly well-suited for individuals focused on those interested in investigational dual agonist therapies with strong early data. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach.
Survodutide
Significant body weight reduction in obesity
Survodutide is particularly well-suited for individuals focused on significant body weight reduction in obesity. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach.
MASH/NASH resolution and liver fibrosis improvement
Survodutide is particularly well-suited for individuals focused on mash/nash resolution and liver fibrosis improvement. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach.
Type 2 diabetes management with concurrent weight loss goals
Survodutide is particularly well-suited for individuals focused on type 2 diabetes management with concurrent weight loss goals. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach.
Enhanced metabolic outcomes through dual receptor engagement
Survodutide is particularly well-suited for individuals focused on enhanced metabolic outcomes through dual receptor engagement. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach.
Safety Profile
Side
effects
Pemvidutide
Common
- Nausea
- Diarrhea
- Headache
Uncommon
- Vomiting
- Decreased Appetite
Serious
- Acute Pancreatitis
- Severe Gastrointestinal Disturbance
Survodutide
Common
- Nausea
- Vomiting
- Diarrhea
- Decreased Appetite
Uncommon
- Constipation and Abdominal Pain
Serious
- Acute Pancreatitis
Research Status
Safety
& evidence
Pemvidutide
Evidence Level
Moderate human trials (Phase 1-2)
FDA Status
Research compound
Safety Overview
Pemvidutide (rzenx, Eli Lilly GLP-1/GCG dual agonist) completed Phase IIb obesity trials with favorable cardiovascular safety profile. Gastrointestinal side effects (nausea, vomiting, diarrhea) occur in 30-40% of subjects, more prominent than GLP-1 monotherapy due to GCG receptor activation. Pancreatitis risk and elevated calcitonin levels require monitoring. No serious cardiac safety signals despite dual receptor activation; heart rate increases of 5-10 bpm observed.
Contraindications
- xPersonal or family history of medullary thyroid carcinoma or MEN2 syndrome
- xKnown hypersensitivity to pemvidutide or formulation components
- xHistory of acute pancreatitis
- xSevere hepatic decompensation (Child-Pugh C cirrhosis)
Survodutide
Evidence Level
Strong human trials (Phase 3 or FDA approved)
FDA Status
Research compound
Safety Overview
Survodutide data comes from Phase 2 obesity and MASH trials with dose-dependent gastrointestinal side effects (nausea up to 75% at highest doses, diarrhea, vomiting) that mirror GLP-1 receptor agonist class effects but occur with greater frequency due to additional glucagon receptor activation increasing energy expenditure. Pancreatitis risk exists as with all GLP-1 agonists—baseline lipase evaluation and patient education on warning signs (persistent upper abdominal pain) are essential. Medullary thyroid carcinoma risk, though theoretical based on GLP-1 class, contraindicates use in MEN 2 or personal thyroid cancer history.
Contraindications
- xPersonal or family history of medullary thyroid carcinoma (GLP-1 class warning)
- xMultiple Endocrine Neoplasia syndrome type 2 (MEN 2)
- xKnown hypersensitivity to survodutide or excipients
- xHistory of pancreatitis (caution advised with GLP-1 receptor agonists)
Decision Guide
Which is
right for you?
Choose Pemvidutide if...
- Adults seeking substantial weight loss without complex dose titration
- Individuals with concurrent MASH/NAFLD and obesity requiring dual-target therapy
- Patients with metabolic syndrome who need comprehensive risk factor improvement
- Those interested in investigational dual agonist therapies with strong early data
Choose Survodutide if...
- Significant body weight reduction in obesity
- MASH/NASH resolution and liver fibrosis improvement
- Type 2 diabetes management with concurrent weight loss goals
- Enhanced metabolic outcomes through dual receptor engagement